-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the Phase 3 SOLO1 trial, olaparib maintenance treatment provided newly diagnosed BRCA mutations in patients with advanced ovarian cancer who had remission after platinum-based chemotherapy and provided significantly longer progression-free survival than the placebo group.
Ovarian cancer
This article analyzes the health-related quality of life (HRQOL) and patient-centered prognostic results of patients in the SOLO1 trial, as well as the impact of radiation disease progression on health.
The SOLO1 trial is a randomized, double-blind phase 3 trial conducted in 118 centers in 15 countries.
From September 3, 2013 to March 6, 2015, a total of 1084 patients were recruited, of which 693 met the requirements.
PFS of the two groups and PFS adjusted for quality of life
PFS of the two groups and PFS adjusted for quality of lifeThe median follow-up time for the olaparib group and the placebo group were 40.
The quality of life adjusted progression-free survival (mean: 29.
For patients with cancer types evaluated in this trial, olaparib maintenance therapy not only provides excellent progression-free survival benefits, but also does not reduce the patient’s quality of life.
Original source:
Michael Friedlander, et al.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050 / GOG 3015 / ENGOT-OV39) in this message
